Working… Menu
Trial record 1 of 1 for:    ML42071 | Multiple Sclerosis
Previous Study | Return to List | Next Study

Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04377555
Recruitment Status : Recruiting
First Posted : May 6, 2020
Last Update Posted : January 20, 2021
Information provided by (Responsible Party):
Genentech, Inc.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 8, 2023
Estimated Study Completion Date : May 9, 2024